Differential profile of PIP4K2A expression in hematological malignancies

Blood Cells, Molecules, and Diseases

Volumn 55, Issue 3, 2015, Pages 228-235

  Lima, Keli ^a   Ribeiro, Daniela Maria ^a   de Melo Campos, Paula ^a   Costa, Fernando Ferreira ^a   Traina, Fabiola ^a   Olalla Saad, Sara Teresinha ^a   de Fátima Sonati, Maria ^a   Machado Neto, João Agostinho ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Alpha; Cell viability; Leukemia; Myelodysplastic syndromes; Phosphatidylinositol; Phosphatidylinositol 5 phosphate 4 kinase; PIP4K2A; Type II

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL 5 PHOSPHATE 4 KINASE 2A; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; PIP4K2A PROTEIN, HUMAN;

5Q- SYNDROME; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; BIOSYNTHESIS; CELL COUNT; GENE EXPRESSION REGULATION; GENETICS; HEMATOLOGIC DISEASE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BONE MARROW CELLS; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEMATOLOGIC NEOPLASMS; HUMANS; MYELODYSPLASTIC SYNDROMES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RNA, MESSENGER;

EID: 84937823475     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2015.06.014     Document Type: Article

References (23)

1. Fiume R., Stijf-Bultsma Y., Shah Z.H., Keune W.J., Jones D.R., Jude J., Divecha N. PIP4K and the role of nuclear phosphoinositides in tumour suppression. Biochim. Biophys. Acta 2015, 1851:898-910.
2. McCrea H.J., De Camilli P. Mutations in phosphoinositide metabolizing enzymes and human disease. Physiology (Bethesda) 2009, 24:8-16.
3. Polak R., Buitenhuis M. The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood 2012, 119:911-923.
4. Fruman D.A., Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 2014, 13:140-156.
5. Liu T.C., Lin P.M., Chang J.G., Lee J.P., Chen T.P., Lin S.F. Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia. Am. J. Hematol. 2000, 63:170-175.
6. Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood 1998, 92:3410-3415.
7. Nakahara Y., Nagai H., Kinoshita T., Uchida T., Hatano S., Murate T., Saito H. Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. Leukemia 1998, 12:1277-1280.
8. Jude J.G., Spencer G.J., Huang X., Somerville T.D., Jones D.R., Divecha N., Somervaille T.C. A targeted knockdown screen of genes coding for phosphoinositide modulators identifies PIP4K2A as required for acute myeloid leukemia cell proliferation and survival. Oncogene 2014, 34:1253-1262.
9. Ling L.E., Schulz J.T., Cantley L.C. Characterization and purification of membrane-associated phosphatidylinositol-4-phosphate kinase from human red blood cells. J. Biol. Chem. 1989, 264:5080-5088.
10. Divecha N., Truong O., Hsuan J.J., Hinchliffe K.A., Irvine R.F. The cloning and sequence of the C isoform of PtdIns4P 5-kinase. Biochem. J. 1995, 309(Pt 3):715-719.
11. Emerling B.M., Hurov J.B., Poulogiannis G., Tsukazawa K.S., Choo-Wing R., Wulf G.M., Bell E.L., Shim H.S., Lamia K.A., Rameh L.E., Bellinger G., Sasaki A.T., Asara J.M., Yuan X., Bullock A., Denicola G.M., Song J., Brown V., Signoretti S., Cantley L.C. Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors. Cell 2013, 155:844-857.
12. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Sole F., Bennett J.M., Bowen D., Fenaux P., Dreyfus F., Kantarjian H., Kuendgen A., Levis A., Malcovati L., Cazzola M., Cermak J., Fonatsch C., Le Beau M.M., Slovak M.L., Krieger O., Luebbert M., Maciejewski J., Magalhaes S.M., Miyazaki Y., Pfeilstocker M., Sekeres M., Sperr W.R., Stauder R., Tauro S., Valent P., Vallespi T., van de Loosdrecht A.A., Germing U., Haase D. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120:2454-2465.
13. Schanz J., Tuchler H., Sole F., Mallo M., Luno E., Cervera J., Granada I., Hildebrandt B., Slovak M.L., Ohyashiki K., Steidl C., Fonatsch C., Pfeilstocker M., Nosslinger T., Valent P., Giagounidis A., Aul C., Lubbert M., Stauder R., Krieger O., Garcia-Manero G., Faderl S., Pierce S., Le Beau M.M., Bennett J.M., Greenberg P., Germing U., Haase D. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J. Clin. Oncol. 2012, 30:820-829.
14. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., Rees J., Hann I., Stevens R., Burnett A., Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
15. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., Vardiman J.W. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, IARC, Lyon. Fourth ed.
16. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
17. Bultsma Y., Keune W.J., Divecha N. PIP4Kbeta interacts with and modulates nuclear localization of the high-activity PtdIns5P-4-kinase isoform PIP4Kalpha. Biochem. J. 2010, 430:223-235.
18. Peretti de Albuquerque Wobeto V., Machado-Neto J.A., Zaccariotto T.R., Ribeiro D.M., da Silva Santos Duarte A., Saad S.T., Costa F.F., de Fatima Sonati M. PIPKIIalpha is widely expressed in hematopoietic-derived cells and may play a role in the expression of alpha- and gamma-globins in K562 cells. Mol. Cell. Biochem. 2014, 393:145-153.
19. Jones D.R., Bultsma Y., Keune W.J., Halstead J.R., Elouarrat D., Mohammed S., Heck A.J., D'Santos C.S., Divecha N. Nuclear PtdIns5P as a transducer of stress signaling: an in vivo role for PIP4Kbeta. Mol. Cell 2006, 23:685-695.
20. Nyakern M., Tazzari P.L., Finelli C., Bosi C., Follo M.Y., Grafone T., Piccaluga P.P., Martinelli G., Cocco L., Martelli A.M. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 2006, 20:230-238.
21. Evangelisti C., Chiarini F., Lonetti A., Buontempo F., Bressanin D., Cappellini A., Orsini E., McCubrey J.A., Martelli A.M. Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review). Int. J. Oncol. 2014, 45:909-918.
22. Zaccariotto T.R., Lanaro C., Albuquerque D.M., Santos M.N., Bezerra M.A., Cunha F.G., Lorand-Metze I., Araujo A.S., Costa F.F., Sonati M.F. Expression profiles of phosphatidylinositol phosphate kinase genes during normal human in vitro erythropoiesis. Genet. Mol. Res. 2012, 11:3861-3868.
23. Keune W.J., Sims A.H., Jones D.R., Bultsma Y., Lynch J.T., Jirstrom K., Landberg G., Divecha N. Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: a role for PIP4K2B in the regulation of E-cadherin expression. Cancer Res. 2013, 73:6913-6925.